Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dapsone
Drug ID BADD_D00580
Description A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
Indications and Usage For the treatment and management of leprosy and dermatitis herpetiformis.
Marketing Status Prescription
ATC Code D10AX05; J04BA02
DrugBank ID DB00250
KEGG ID D00592
MeSH ID D003622
PubChem ID 2955
TTD Drug ID D0MA9N
NDC Product Code 51927-0084; 70954-135; 49938-102; 65571-0021; 51552-1042; 46438-0645; 49938-101; 49452-2439; 43353-222; 16110-367; 76072-1018; 51927-4368; 53596-014; 70954-136; 58159-033; 51927-0083; 60758-670; 60429-496; 60429-495; 0904-7018; 43353-223; 14474-026; 16714-956; 71052-100; 50218-008; 51672-4197; 29967-0007; 51672-4198; 14474-038; 0023-3670; 0023-5206; 68308-342; 10695-047; 51672-1388; 45562-1120; 51927-0085; 73309-094; 13668-605; 51672-1387; 29033-036; 29033-037; 16110-526; 51672-5307; 0904-7019; 72375-0006
Synonyms Dapsone | DADPS | Sulfonyldianiline | Diaminodiphenylsulfone | Diaphenylsulfone | 4,4'-Diaminophenyl Sulfone | 4,4' Diaminophenyl Sulfone | Sulfone, 4,4'-Diaminophenyl | Sulfona | Dapson-Fatol | Disulone | Avlosulfone | Dapsoderm-X
Chemical Information
Molecular Formula C12H12N2O2S
CAS Registry Number 80-08-0
SMILES C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AgranulocytosisMyeloperoxidaseP05164T234717902244; 1664258; 8385460; 2856515; 1650217; 9022075; 1324677; 12060654; 11440179; 9243259; 16214851
HypersensitivityN-alpha-acetyltransferase 20P61599Not AvailableNot Available
Lupus erythematosus (incl subtypes)MyeloperoxidaseP05164T234717902244; 1664258; 8385460; 2856515; 1650217; 9022075; 1324677; 12060654; 11440179; 9243259; 16214851
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin lesion23.03.03.0100.001603%Not Available
Skin necrosis23.03.03.0110.002405%Not Available
Suicide attempt19.12.01.004--
Swelling face23.04.01.018; 10.01.05.0180.003207%Not Available
Tachycardia02.03.02.0070.004008%Not Available
Tachypnoea22.02.01.0140.001603%Not Available
Thrombocytopenia01.08.01.0020.004008%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000837%
Type I hypersensitivity10.01.03.0060.001603%Not Available
Urticaria23.04.02.001; 10.01.06.0010.007215%
Ventricular arrhythmia02.03.04.0060.001603%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.0030.006414%
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.011--Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Tonic clonic movements17.12.03.006--Not Available
Nerve injury12.01.12.002; 17.02.10.007--Not Available
Protein urine present13.13.02.006--Not Available
Vanishing bile duct syndrome09.02.03.0030.005612%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.004810%Not Available
Red blood cell abnormality01.07.02.006--Not Available
Disease progression08.01.03.038--
Psychotic disorder19.03.01.002--
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.001603%Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Bone marrow failure01.03.03.0050.001603%
Liver injury12.01.02.003; 09.01.07.0220.001603%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages